b-Globin locus control region (LCR) sequences have been widely used for the regulated expression of the human b-globin gene in therapeutic viral vectors. In this study, we compare the expression of the human b-globin gene from either the HS2/HS3 b-globin LCR or the HS40 regulatory element from the a-globin locus in the context of foamy virus (FV) vectors for the genetic correction of b-thalassemia. Both regulatory elements expressed comparable levels of human b-globin in a murine erythroleukemic line, whereas in murine hematopoietic stem cells the HS40.b vector proved more efficient in b-globin expression and correction of the b-thalassemia phenotype. Following transplantation in the Hbb th3/+ mouse model, the expression efficiency by the two vectors was similar, whereas the HS40.b vector achieved relatively more stable transgene expression. In addition, in an ex vivo assay using CD34+ cells from thalassemic patients, both vectors achieved significant human b-globin expression and restoration of the thalassemic phenotype as evidenced by enhanced erythropoiesis and decreased apoptosis. Our data suggest that FV vectors with the a-globin HS40 element can be used as alternative but equally efficient vehicles for human b-globin gene expression for the genetic correction of b-thalassemia.
INTRODUCTION b-Thalassemia syndromes are a group of hereditary blood disorders characterized by deficient synthesis of the hemoglobin b-chain and chronic hemolysis. b-Thalassemias are considered the most common monogenic disorders worldwide and are inherited in an autosomal recessive manner. The defective synthesis of hemoglobin b-chains in the erythroid progenitors results in the accumulation and precipitation of excess a-chains, causing damage to the developing red blood cell membrane and a syndrome of chronic hemolysis with reduced or complete absence of adult hemoglobin. Patients with thalassemia major, the most severe form, require regular blood transfusions that not only affect the quality of life but also are often accompanied by life-threatening side effects such as iron overload in vital organs. Allogeneic bone marrow transplantation, when available, is the only therapeutic approach, which, however, is accompanied with severe morbidity and may be complicated with graft versus host disease. 1 As a result, alternative treatment options for b-thalassemia have been developed, and therapeutic b-globin vectors have been constructed and tested for over two decades. Accomplishments in globin gene regulation have paved the way toward b-thalassemia gene therapy, as obstacles such as low vector titers, vector stability and efficient transgene expression have been tackled. Retroviral vectors designed for the expression of b-or g-globin genes had been plagued with low expression until the requirement for the inclusion of regulatory elements from the b-globin locus control region (LCR) was realized. 2, 3 The HS2 and HS3 are the minimum regulatory sequences required for efficient expression of the b-globin gene in the Hbb th3/+ mouse model of b-thalassemia and in patient samples. 4, 5 The discovery of the a-globin locus HS40 enhancer provided an alternative regulatory element for the expression of globin genes with variable success. [6] [7] [8] In this study, we have used foamy virus (FV) vectors, 9 a nonpathogenic genus of retroviruses, to provide a detailed comparison of the a-globin HS40 sequence and the b-globin LCR HS2 and HS3 sequences for the efficient expression of human b-globin gene. FV vectors transduce hematopoietic stem cells (HSCs) of murine, canine or human origin, [10] [11] [12] and show reduced tendency to integrate in gene-coding sequences, constituting safer alternative gene transfer vehicles to g-retroviral vectors. 13 We demonstrate that in the context of FV vectors, the HS40 element is marginally more efficient than the combination of HS2/HS3, both ex vivo in murine HSCs and human CD34+ cells, as well as in the Hbb th3/+ mouse model of b-thalassemia. Given the compact size of the HS40 element, we propose that it can be used alternatively to the LCR sequences for regulated b-globin expression in gene therapy approaches with FV vectors.
RESULTS

Evaluation of human b-globin-expressing FV vectors in MEL cell line
We constructed and tested two FV vectors combining elements from both a-and b-globin loci; in the pDF.HS40.b vector, expression of the b-globin gene was driven by the native b-globin promoter and regulated by the HS40 sequence of the human a-globin locus (Figure 1a) , whereas in the pDF.HS2.HS3.b vector the core HS2 and HS3 regulatory elements from the b-globin LCR were used. The titers of the FV vectors were estimated by real-time PCR to be 3.8Â10 6 IU ml À1 and 2.5Â10 6 IU ml À1 for HS40.b and HS2.HS3.b, respectively (Figure 1b) . Initially, b-globin expression analysis by flow cytometry was tested in single-cell clones of the mouse erythroleukemia cell line (MEL) following transduction at low multiplicity of infection (MOI; p5) and compared with non-transduced clones as well as to a positive control. 14 Efficient production of human b-globin was observed with both the vectors compared with the MEL-YACbGLO-positive control; expression levels varied from 36 to 100% of our positive control as estimated by the mean fluorescence intensity following antibody staining (Figure 1c ). In the vast majority of the clones, this expression was achieved with a vector copy number (VCN) of 1-3, as evaluated by Taqman real-time PCR. When we calculated the b-globin mean fluorescence intensity levels per integrated VCN, we observed a 65 ± 16% increase in b-globin expression with the HS40.b vector over the untransduced cells and 55 ± 12% with the HS2.HS3.b vector (Figure 1d ). These findings indicated that both vectors can support the expression of human b-globin gene in the MEL cellular environment.
Transduction and ex vivo culture of primary mouse HSCs
To test the efficiency of b-globin expression from our FV vectors in primary hematopoietic progenitors, we transduced bone marrow lineage-depleted (LinÀ) cells from Hbb th3/+ mice with both vectors at similar MOIs (p10). Following culture in methylcellulose medium, we harvested the erythroid burst-forming units colonies, calculated human b-globin mRNA expression via Taqman real-time PCR and expressed it relative to the endogenous mouse a-globin mRNA. The HS40.b vector achieved higher b-globin expression (12 ± 3.4%) compared with the HS2.HS3.b vector (2±0.5%, P¼0.014, Figure 2a) .
We next isolated the CD11b+ cell fraction from homozygous Hbb th3/th3 E13.5 mouse embryonic fetal liver cells (FLCs) that are enriched in long-term HSCs. 15 To elucidate whether our b-globinexpressing FV vectors have the ability to restore the ineffective erythropoiesis in this mouse model, we analyzed erythroid differentiation by antibody staining for the erythropoietic markers CD71 and Ter119 by flow cytometry. 16 To this end, we transduced FLCs at low MOI (o3) and cultured them in medium containing cytokines that drive erythroid differentiation. In this system, on day 6 of FLC culture, HS40.b-transduced cells demonstrated slightly higher number of total CD71+ erythroid-committed progenitors (gates I and II of Figure 2b , 62.3%) compared with non-transduced FLCs (Figure 2b , 56.9%). On day 9, HS40.b-transduced FLCs showed a 21% increase in the CD71+ cells, while at the same time HS2.HS3.b-transduced cells exhibited a 4% increase in comparison with the non-transduced population. Collectively, these data indicate that both FV vectors can produce human b-globin at levels that can ameliorate the ineffective erythropoiesis seen in thalassemic cells. However, in the murine HSCs ex vivo, the HS40.b vector expressed higher levels of b-globin and restored more effectively the impaired erythropoiesis of the thalassemic FLCs. Transduced cells were transplanted to C57Bl6J recipients conditioned with busulfan, using an adapted clinically relevant protocol, 17, 18 and were monitored for expression of human b-globin by flow cytometry in the peripheral blood (PB); values are expressed as percentage of a human PB sample (Figure 3a) .
Animals that had received BM LinÀ cells transduced with the HS40.b vector expressed human b-globin at an average of 30% at 7-12 weeks following transplantation and 43% when they were killed Figure 3d ). To further verify the functional aspect of the human b-globin protein produced in vivo by the FV vectors, we performed western blot analysis for the detection of both human b-and mouse a-globin. A non-denaturing acrylamide gel was used to maintain the entire hemoglobin protein intact, and the same transplanted animal samples were immune stained for human b-and mouse a-globin. We found that the PB samples from our transplanted animals gave a single hemoglobin band that was positive for both human b-and mouse a-globin. This indicated that in animals transplanted with genecorrected HSCs, human b-globin chains formed a hybrid tetramer with mouse a-globin chains (Figure 3e ).
Evaluation of b-globin FV vectors in human thalassemic HSCs
To assess the effectiveness of the FV vectors to express human b-globin in a preclinical setting of human b-thalassemia, we transduced HSCs from human b-thalassemia major patients. CD34+ cells were isolated from BM or PB patient samples and transduced with the HS40.b and HS2.HS3.b vectors at low MOI (5-10). Cells were cultured under erythropoietic conditions, and at different time points (days 9-18), the levels of human b-globin were assayed by flow cytometry, alongside the evaluation of erythropoiesis with glycophorin A (GlyA) and CD71 analysis. Control thalassemic CD34+ cells showed basal levels of b-globin expression that accounted for 9±0.1% of the total population. Transduction with the FV vectors resulted in a threefold increase in b-globin expression levels per VCN with the HS40.b vector (26 ± 8.9%) and in a fourfold increase with the (Figure 4d ). These findings show that in human thalassemic samples both vectors expressed b-globin at comparable levels that were adequate for the restoration of ineffective erythropoiesis.
We then correlated the GlyA and CD71 expression pattern with the hierarchy of erythropoietic maturation: basophilic erythroblasts (GlyA high /CD71 high ), polychromatophilic erythroblasts (GlyA high / CD71 med ) and orthochromatic erythroblasts (GlyA high /CD71 low ). 19 In the control thalassemic sample, the basophilic erythroblast subpopulation constituted 62.4% of the entire population, whereas the polychromatophilic and orthochromatic erythroblasts 14.7% and 11.6%, respectively (Figure 4e) . In HS40.b-transduced cells, the basophilic erythroblast population was reduced to 31.2% of the entire cohort, whereas the polychromatophilic and orthochromatic cell populations were increased to 29.6% and 38.4%, respectively. Similarly, transduction with the HS2.HS3.b vector gave 46.9% of basophilic erythroblasts, 22.9% polychromatophilic and 29.3% orthochromatic erythroblasts, again indicating that b-globin expression by any of the two FV vectors in thalassemic CD34+ cells was capable of restoring erythropoietic maturation. A further characteristic of thalassemic CD34+ cells is their tendency to undergo apoptosis due to their inability to reach full erythroid maturation. 20 Apoptosis was measured by flow cytometry analysis for Annexin-V at 16 days following erythropoietic culture. HS40.b-and HS2.HS3.b-transduced thalassemic CD34+ cells were found to contain reduced amount of apoptotic cells, 15.6% and 6.8%, respectively, compared with 26.8% of apoptotic cells seen in the control sample (Figure 4f ). DISCUSSION b-Thalassemia gene therapy has been envisioned for over 20 years, 21 but vector stability, low titers and transgene expression issues have delayed its application. 18 Human b-globin was initially expressed using only the homologous promoter without any additional regulatory elements. [22] [23] [24] Over the years, the importance of the LCR sequence in the regulated expression of the human b-globin gene was demonstrated, alongside the discovery and utilization of the core elements of the different hypersensitive sites of the LCR sequence. 2, [25] [26] [27] [28] The combination of core sequences from the HS2, HS3 and HS4 elements led to the construction of the first retroviral vectors with high titer, vector stability and efficient expression of the human b-globin transgene. 29, 30 On another approach that was implemented during the same time, the HS40 regulatory element from the a-globin locus that drives tissue-specific globin gene expression, 31, 32 was used to support expression of different globin genes. 8, 33 In this study, we have used FV vectors to compare the efficiency of b-globin expression from a short (À127) b-globin gene promoter 33 regulated by either the HS40 a-globin enhancer or the HS2/HS3 regulatory sequences from the b-globin LCR. It was our original hypothesis that vectors harboring regulatory elements from both coordinately expressed globin genes would have optimal performance. To test our hypothesis, we constructed the HS40.b vector and compared it with a standard HS2.HS3.b vector. The titers of the HS40.b and HS2.HS3.b FV vectors were similar, indicating that these two regulatory elements have little impact on FV vector packaging. The efficiency of our FV vectors was initially tested in vitro in the erythroid cell line MEL, where we found that both vectors expressed comparable levels of b-globin. Our results are in accordance with previous studies comparing the efficiency of the HS40 sequence and the HS2 and HS3 sequences to regulate expression of b-and g-globin in MEL cells. 33 We next transduced ex vivo BM HSCs isolated from the Hbb th3/+ mouse model of b-thalassemia intermedia. Progenitor erythroid colonies (day 10 burst-forming units) transduced with the HS40.b and HS2.HS3.b vectors expressed human b-globin mRNA at 12% and 2%, respectively, of the endogenous mouse a-globin. For pure technical reasons, expression in this assay could not be correlated to VCN due to residual FV plasmid contamination of the erythroid colonies. Nevertheless, this data indicated that both our FV vectors could express human b-globin with the HS40.b vector regulating such expression more efficiently in the mouse hematopoietic cell context. We also transduced a HSC-enriched population of FLCs isolated from Hbb th3/th3 E13.5 embryos, which was subsequently cultured under erythropoietic conditions. Transduced FLCs showed increased number of proerythroblasts (day 6) and basophilic erythroblasts (day 9) in comparison with the thalassemic control population. Collectively, these findings showed that both FV vectors managed to restore the ineffective erythropoiesis of thalassemic HSCs, but the HS40.b-transduced FLCs exhibited an improved erythropoiesis profile due to the more efficient b-globin production.
Using a similar construct to our HS2.HS3.b FV vector on a lentivirus vector backbone, Ferrari and colleagues 4 achieved human b-globin expression in over 90% of PB cells following transplantation in lethally irradiated recipients. We utilized the same model of b-thalassemia to show that transplantation of FV-transduced BM LinÀ HSCs resulted in 26.6% and 17.6% of human b-globin-expressing cells in the PB when HS40.b and HS2.HS3.b vectors were used, respectively. It is worth noting that these expression levels were obtained using a partially myeloablative regime with an average bone marrow chimerism of 47% (range 17-80%) in wild-type hosts. Studies in the Hbb th3/+ mouse model indicate that 10-20% of genecorrected HSCs are sufficient to improve the intermediate thalassemia phenotype. 4, 34 Also in patients with severe thalassemia (b 0 ), the presence of nearly 25% of normal transplanted cells significantly improves the production of adult hemoglobin. 35 Although both our FV vectors achieved b-globin expression close to that threshold, due to the low engraftment rate, the hematological parameters of the transplanted animals resembled those of wild-type hosts. A thalassemic phenotype in the chimeric setting requires the presence of more than 50% of affected cells. 34 Nevertheless, non-denaturing polyacrylamide gel electrophoresis analysis of PB from our transplanted animals indicated the formation of hybrid hemoglobin tetramers.
In transplantation experiments with E13.5 Hbb th3/th3 FLCs, human b-globin in the PB reached an average of 11.4% for the HS40.b vector and 7.2% for the HS2.HS3.b vector. The differences in b-globin expression observed between transplantation of BM and FL HSCs purely reflect variations in engraftment rates achieved with the two HSC populations rather than gene transfer or developmental regulatory differences. Such reduction in engraftment and hence globin expression following transplantation with FLCs has been reported before. 36 Transduction of human CD34+ cells isolated from b-thalassemia patients (b 0 ) showed efficient b-globin expression following erythroid liquid culture by either of the FV vector-encoded regulatory elements. This restored the ineffective erythropoiesis seen in thalassemic cells by promoting the development of a CD71 low GlyA high cell population and reducing apoptosis. It is noteworthy that such phenotypic improvement was achieved with a VCN of 1. The use of b-globin LCR elements for b-globin expression in thalassemic patient samples has been documented before, 5, 20 but our study constitutes the first report on the successful use of the a-globin HS40 regulatory element for the functional correction of b-thalassemia in human primary samples.
Contrary to what has been speculated before about the inability of the HS40 element to drive transcription of the fetal g-globin in vivo following BMT or in transgenic animals, we found that this element, in the context of FV vectors, provided adult b-globin expression comparable to the HS2.HS3 element. This suggested that the HS40 transcriptional regulation may occur in a gene-context manner. In addition, the HS40 element does not have a chromatin opening activity, although this is a debatable condition for murine b-globin expression. 37 However, in our case, one cannot exclude the contribution of the proviral FV long terminal repeat in 'insulating' the transgene 38 and maintaining such an open chromatin conformation. This allows for a direct comparison of the transcriptional activity between the HS40 and HS2.HS3 elements. In conclusion, our data show that the HS40 constitutes a compact and strong enhancer compared with the larger and more complex HS2.HS3. In the context of the FV vector, HS40 provides stable expression following transplantation and is a potent regulatory element for b-globin expression.
Globin gene therapy has been in the forefront of therapeutic vector development. Retroviral vectors were initially explored as therapeutic vehicles but were met with unsurpassed obstacles in titers, stability and expression. 3, 29, 39, 40 Lentiviral globin vectors were then successfully explored in the preclinical mouse and more recently in the clinical arena; 18, 30 however, globin expression was also accompanied by the unwanted overexpression of a gene (HMGA2) that may culminate to a malignant disorder. FV vectors are the less well explored genus of retroviruses and their therapeutic potential has not yet been explored in the clinic; however, we show that FV vectors can provide therapeutic levels of hemoglobin in the thal3 mouse model and, similarly to the lentiviral vectors, 4 with low VCNs (o2). Along with the lack of pathogenicity, efficient expression with low vector copies is a much desired feature in any therapeutic vector that holds promise for clinical application. In effect, FV vectors are an alternative to lentiviral vectors and could be further explored in the 'additive' gene transfer field.
MATERIALS AND METHODS
Cell lines and differentiation conditions
The mouse erythroleukemia (MEL) cell line was grown in RPMI complemented with 10% heat-inactivated fetal bovine serum, 2 mM L-glutamine and 1% PenStrep (100 U ml À1 penicillin and 100 mg ml À1 streptomycin; all by GIBCO, Invitrogen, Carlsbad, CA, USA). For erythroid differentiation, logarithmically growing cells were exposed to 2% dimethylsulfoxide (Carlo Erba, Val de Reuil, France) for 4 days. 293T and HT1080 cells were cultured in Dulbecco's modified Eagle's medium (GIBCO) with identical supplements as stated above.
Foamy viral vectors and vector production
Self-inactivating FV vectors were generated as previously described. 41 The pDF.Lb vector that codes for the human b-globin gene under the regulation of an extended LCR cassette was used as a backbone. A sequence containing the HS40 element (425 bp) along with the À127 bp b-globin promoter was isolated as a NotI-NcoI fragment from a vector kindly gifted by Dr DW Emery 33 and inserted into the pDF.Lb backbone, replacing the LCR cassette and generating the pDF.HS40.b vector. The HS2 (756 bp) and HS3 (1334 bp) sequences were isolated as a single PCR fragment from the pDF.Lb LCR cassette using primers with XbaI and NotI restriction enzyme identification sequences (forward (F): 5¢-GCCGGGTCTAGACATTTGATTCACAAT-3¢ and reverse (R): 5¢-CTAAGCG GCCGCCTAGTGCTTAGATTC-3¢). The HS2/HS3 sequence replaced the HS40 element in the pDF.HS40.b vector, generating the pDF.HS2.HS3.b vector. The entire human b-globin gene expression cassette was integrated in reverse orientation in respect to the foamy transcription. FV vector stocks were generated by calcium phosphate-mediated transient transfection in 293T cells as described. 41 
Flow cytometry
Human b-globin expression was determined by intracellular staining with mouse monoclonal PE conjugated antibody (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA). MEL cells, human CD34+ cells from patients or PB from transplanted animals were fixed with 4% paraformaldehyde for 30 or 10 min at room temperature, respectively. Fixed PB was permeabilized with 1:4 methanol:acetone solution for 2 min at room temperature, MEL cells and human CD34+ cells with 0.1% Triton X for 15 min and followed by a 30-min incubation with the anti-human b-globin antibody at 4 1C. The stained PB samples were analyzed by flow cytometry, and in every set, there was a negative and a positive control, that is, wild-type mouse samples and human PB samples. Acquisition and analysis of human b-globin expression was performed on a FC500 flow cytometer (Beckman Coulter, Brea, CA, USA).
Isolation, transduction and ex vivo erythroid differentiation of mouse primary hematopoietic progenitor cells
Murine bone marrow cells were harvested from the femurs and tibias of Hbb th3/+ mice (kindly provided by Professor NA Anagnou) at approximately 7-10 weeks of age. BM LinÀ progenitors were isolated using a StemSep mouse progenitor enrichment cocktail (STEMCELL Technologies, Vancouver, Canada) following the manufacturer's instructions. FLCs were isolated from E13.5 Hbb th3/th3 embryos and were subsequently selected for CD11b (BD Pharmingen, Franklin Lakes, NJ, USA) using streptavidin-coated beads and MS Macs columns (both from Miltenyi Biotec, Bergisch Gladbach, Germany). BM LinÀ or FLC CD11b+ cells were transduced in StemSpan (STEMCELL Technologies) serum-free medium supplemented with 1% PenStrep, 5% fetal calf serum and murine SCF at 10 ng ml À1 , human IL6 at 10 ng ml À1 , human Flt3L at 50 ng ml À1 (all by PeproTech EC Ltd, London, UK) at an MOI of 3-10 on retronectin-coated plates (CH296, Takara Bio Inc., Otsu, Japan). The following day transduced or control BM LinÀ cells were plated at 10 3 ml À1 in methylcellulose medium (MethoCult, STEMCELL Technologies) and transduced FLC CD11b+ cells were cultured in StemSpan medium supplemented with 1% PenStrep, 5% fetal calf serum and the following cytokines at final concentrations as indicated. Growth phase: EPO 0.5 U ml À1 (NeoRecormon, Roche, Basel, Switzerland), muSCF 100 ng ml À1 and dexamethasone 10 À6 M (Sigma-Aldrich, Taufkirchen, Germany); differentiation phase: EPO 10 U ml À1 . FLC CD11b+ cells were maintained in growth culture for up to 6 days and in erythroid differentiation culture for another 3 days at a concentration of 3-10Â10 5 ml À1 .
Transplantation of transduced BM LinÀ cells in Hbb th3/+ mice
Animals were kept at the BRFAA Animal Facility in microisolator cages provided with irradiated food and autoclaved water. Experiments were approved by the Institutional and the National Review Board committee. Myeloablation was performed using Busilvex (Pierre Fabre Médicament, Boulogne, France) following careful titration of the tolerated dose in normal C57Bl6J animals. Busilvex doses 480 mg per kg total were found to induce toxic death within 48 h. Daily intraperitoneal injections of 20 mg À1 per kg Busilvex for 4 days before the transplantation in female C57Bl6J mice (7-10 weeks) resulted in partial myeloablation (data not shown). Following transduction, cells were washed in phosphate-buffered saline and 0.5-2Â10 5 cells were injected intravenously in partially myeloablated recipients. Mice were killed at weeks 18-25 after transplantation.
Western blot
A volume of 10 ml of PB was lysed by the addition of 40 ml Hemolysate Reagent (Helena Laboratories, Beaumont, TX, USA) and the hemolysate was equally divided on two non-denaturing, 12% polyacrylamide gels and transferred to PVDF membranes (Roche) for 30 min at 4 1C. Membranes were blocked with tris-buffered saline with Tween 20 containing 5% non-fat dry milk for 2 h at 4 1C. One membrane was stained for human b-globin (1:1000) and the other for mouse a-globin (1:500; both antibodies by Santa Cruz Biotechnology) by overnight incubation at 4 1C in tris-buffered saline with Tween 20/5% non-fat dry milk. A horseradish peroxidase-conjugated secondary antibody (1:5000) was added for 2 h at room temperature and the bands were visualized using Amersham ECL western blotting detection system (GE Healthcare, Waukesha, WI, USA).
Isolation, transduction and ex vivo erythroid differentiation of human primary hematopoietic progenitor cells PB samples from human b-thalassemia major (b 0 ) patients were collected during regular hospital visits and were used to isolate CD34-positive cells (CD34 Microbead kit, Miltenyi Biotec). CD34+ thalassemic cells were incubated with concentrated FV stocks for 18-20 h with the addition of huFlt3L at 100 ng ml À1 , huSCF at 100 ng ml À1 , huTPO at 100 ng ml À1 , huIL-6 at 20 ng ml À1 and huIL-3 at 20 ng ml À1 (PeproTech EC Ltd). The next day, transduced cells were washed with phosphate-buffered saline and cultured in StemSpan medium supplemented with 1% PenStrep, 5% fetal calf serum and the following cytokines at final concentrations as indicated, EPO 1 U ml À1 , huSCF 10 ng ml À1 , huIL-3 10 ng ml À1 and either dexamethasone 10 À6 M and b-estradiol 1 mM (Sigma-Aldrich) or huTPO 10 ng ml À1 and huFlt3L 10 ng/ml. CD34+ cells were maintained in culture for 16-18 days and at a concentration of 1-3Â10 5 ml À1 .
Taqman real-time PCR
For VCN and BM engraftment determination, genomic DNA from transduced cells or BM of transplanted mice was extracted and 250 ng was amplified in duplicate 25 ml reactions using an ABI Prism 7000 instrument (Applied Biosystems, Carlsbad, CA, USA). Detection of endogenous mouse GAPDH gene (Rodent GAPDH kit, ABI), the FV genome (F: 5¢-CTGGAATGTTACT CAAAGAGCTGTTT-3¢ and R: 5¢-TGGAACAGGATGCTGCATTCT-3¢) and in the case of BMT animals the TSPY gene (F: 5¢-TCCTTGGGCTCTTCAT TATTCTTAAC-3¢ and R: 5¢-GAGAACCACGTTGGTTTGAGATG-3¢) were performed using QPCR and SYBR Green master mixes, respectively (ABI or Stratagene, Santa Clara, CA, USA). Standards on the basis of different amounts of a FV vector plasmid (FV genome) or genomic DNA of mouse origin were also analyzed and their threshold cycle (Ct) values were plotted in standard curves. These were then used to extrapolate the absolute VCN and number of cells per reaction, respectively. In addition, a plot of increasing concentration of TSPY gene was performed for the engraftment levels in the transplanted mice, to be calculated as previously shown.
For the detection of human b-globin and murine a-globin mRNA, RNA was extracted from transduced or control day 10 burst-forming units using TriReagent (Molecular Research Center, Cincinnati, OH, USA) and reverse transcribed using MMLV-RT (Promega, Madison, WI, USA) according to the manufacturer's recommendations. The levels of human b-globin and murine a-globin mRNA were analyzed using SYBR Green Master mix and primers: Hu-b: (F: 5¢-GGTGAATTCTTTGCCAAAGTGAT-3¢ and R: 5¢-CACCTTTGC CACACTGAGTGA-3¢) and Mu-a: (F: 5¢-ACCTACTTTCCTCACTTTGATG TAAGC-3¢ and R: 5¢-GCATCGGCGACCTTCTTG-3¢). The relative expression of human b-globin over murine a-globin expression was calculated using the 2 ÀDDCt method developed by Livak et al. 42 
